<DOC>
	<DOCNO>NCT02796950</DOCNO>
	<brief_summary>Glucagon like peptide 1 produce enteroendocrine L cell small intestine stimulate peroral food intake . GLP-1 induces insulin secretion , analogue use treatment DM2 ( type 2 diabetes mellitus ) . Recently find , level GLP-1 increase response acipimox . The hypothesis G protein couple receptor enteroendocrine L cell bind acipimox thereby induce GLP-1 secretion . In controlled , open , randomized experiment , eight healthy , overweight men study intervention day , receive acipimox , control day . The study day include OGTT ( oral glucose tolerance test ) , blood sample OGTT biopsy adipose tissue .</brief_summary>
	<brief_title>The Effect Acipimox GLP ( Glucagon-like Peptide ) -1 Secretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acipimox</mesh_term>
	<criteria>Adult men Healthy BMI 2535 Known DM2 Receiving hypolipidemic drug</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acipimox</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Insulin secretion</keyword>
</DOC>